Harvard 21st Biennial course in Urologic Oncology 2022

Overview

The Harvard 21st Biennial Course in Urologic Oncology 2022 is a comprehensive multidisciplinary educational event that integrates expertise from Harvard teaching hospitals along with internationally recognized specialists in urologic oncology, medical oncology, and radiation oncology. This course continues a legacy that began in 1982, featuring keynotes by distinguished scholars including Dr. George Daley, Dean of Harvard Medical School, and Dr. Lindsey Baden, Principal Investigator of the Covid Moderna Trial.

On-demand urologic oncology education — accessible anytime, anywhere.

Agenda

This course offers a detailed agenda focusing on the latest clinical advances and management strategies in urologic oncology. All sessions adhere to Eastern Time scheduling.

• Registration — Anthony D’Amico
• Welcome — Anthony D’Amico
• Epidemiology and Genetics — Lorelei Mucci
• Screening in 2022: Role of PSA and Novel Biomarkers — Adam Kibel
• Advances in Multiparametric MRI for Diagnosis and Staging — Clare Tempany
• Interpreting Prostate Biopsy Reports — Michelle Hirsch
• Expert Panel: Screening and Diagnosis — Moderator: Anthony D’Amico; Speakers: Michelle Hirsch, Adam Kibel, Lorelei Mucci, Clare Tempany
• Break
• Focal Ablation and Active Surveillance in Intermediate Risk Disease — Alexander Cole
• Radical Prostatectomy in Intermediate Risk Disease — Quoc-Dien Trinh
• Hypofractionation and ADT use in Intermediate Risk Prostate Cancer — Neil Martin
• MRI Guided Radiation Therapy — Jonathan Leeman
• Optimizing Systemic Therapy in the Management of Intermediate and High-Risk Prostate Cancer — Anthony D’Amico
• Novel Approaches in the Preoperative Setting for the High-Risk Patient — Mary-Ellen Taplin
• Biomarker Based Clinical Trials and Prostate Cancer — Martin Gleave
• Expert Panel: Patient Selection — Moderator: Anthony D’Amico; Speakers: Alexander Cole, Martin Gleave, Jonathan Leeman, Neil Martin, Mary-Ellen Taplin, Quoc-Dien Trinh
• Lunch
• PET Imaging in the PSA Recurrent Setting-Diagnostics — Heather Jacene
• Treatment of Oligometastatic Disease, Integration of Surgery — Martin Gleave
• Treatment of Oligometastatic Disease, Integration of Radiation — Paul Nguyen
• Precision Medicine in Prostate Cancer — Himisha Beltran
• Expert Panel: Updates in Diagnostics and Special Populations — Moderator: Adam Kibel; Speakers: Himisha Beltran, Martin Gleave, Heather Jacene, Paul Nguyen
• Break
• Adjuvant versus Salvage Radiation — Anthony D’Amico
• Management of the Rising PSA in the Patient with M0 Castrate Sensitive Prostate Cancer — Charles Ryan
• Management of Advanced Prostate Cancer in the Elderly — Alicia Morgans
• Survivorship and Side Effects of ADT — Phil Saylor
• Management of Side Effects of Radical Prostatectomy in the Denovo and Recurrent Settings — Peter Chang
• Management of Side Effects of Radiation Therapy in the Denovo and Recurrent Settings — Daniel Schmidt
• Management of the Side Effects of Non-ADT Systemic Treatment for Prostate Cancer — Mark Pomerantz
• Expert Panel: Management of Treatment Related Toxicity and Recurrent Disease — Moderator: Adam Kibel; Speakers: Peter Chang, Anthony D’Amico, Alicia Morgans, Mark Pomerantz, Charles Ryan, Phil Saylor, Daniel Schmidt
• Management of the Rising PSA in the Patient with M0 Castrate Resistant Prostate Cancer — Atish Choudhury
• Personalizing Treatment Selection in Metastatic, Hormone-sensitive Prostate Cancer — Christopher Sweeney
• Immunotherapy for Prostate Cancer — Xiao Wei
• Novel Androgen Receptor Targeted Therapy of Castrate Resistant M1 Prostate Cancer
• PET Imaging in the PSA Recurrent Setting – Therapeutics — Praful Ravi
• Expert Panel: Management of Metastatic Prostate Cancer — Moderator: Glenn Bubley; Speakers: Atish Choudhury, Praful Ravi, Charles Ryan, Christopher Sweeney, Xiao Wei
• Break
• Special Lecture, Kidney Development and Wilms Tumor: Prospects for Regeneration — George Daley
• Role of Biomarkers in Diagnosis and Follow-up — Adam Feldman
• Management of Superficial Bladder Cancer — Angela Smith
• Genomics and Its Role in the Management of Bladder Cancer — Joaquim Bellmunt
• Management of Upper Tract Disease — Matthew Mossanen
• Urinary Diversion after Cystectomy, Choices and Outcomes — Andrew Wagner
• Lymph Node Dissection and Approaches to Radical Cystectomy — Mark Preston
• Lunch
• Judah Folkman Lecture: Emerging Strategies in the Fight Against Covid-19 — Lindsey Baden
• Genomic Predictors of Response to Chemotherapy — Kent Mouw
• Personalizing Bladder Cancer Treatment in Variant Histology — Angela Smith
• Neoadjuvant and Adjuvant Chemotherapy — Richard Lee
• Bladder Sparing Approaches — Jason Efstathiou
• Chemo and Immunotherapy for Advanced Urothelial Cancer — Joaquim Bellmunt
• Expert Panel: Bladder Cancer — Moderator: Adam Kibel; Speakers: Joaquim Bellmunt, Jason Efstathiou, Adam Feldman, Richard Lee, Kent Mouw, Matthew Mossanen, Mark Preston, Angela Smith, Andrew Wagner
• Break
• Management of Seminoma — Alok Tewari
• Management of Stage I Non-seminoma — Timothy Clinton
• Updates in Radiation Therapy in Testis Cancer — Sophia Kamran
• Management of Advanced Disease-Chemotherapy — Christopher Sweeney
• Emerging Role of Genomics in Testis Cancer — Eliezer Van Allen
• Expert Panel: Testis Cancer — Moderator: Jerome Richie; Speakers: Timothy Clinton, Sophia Kamran, Christopher Sweeney, Alok Tewari, Eliezer Van Allen
• Tackling Tumor Metabolism in Renal Cell Carcinoma — Kimryn Rathmell
• Updates in the Pathology Classification of Renal Cell Cancer — Michelle Hirsch
• Role of Observation and Ablation for Small Renal Mass — Aria Olumi
• Radical or Partial Nephrectomy: Techniques and Innovations — Steven Chang
• Managing the Primary when Metastatic and Metastatectomy — Keyan Salari
• Adjuvant Strategies in RCC — Toni Choueiri
• Break
• Advanced Disease: First Line Options — Vincent Xu
• Advanced Disease: Post IO Setting — David McDermott
• Non Clear Cell RCC — Bradley McGregor
• Novel Targets Beyond Targeted Agents and IO Drugs — Xin Gao
• Expert Panel: Renal Cell Carcinoma — Moderator: Tonu Choueiri; Speakers: Steven Chang, Xin Gao, Michelle Hirsch, David McDermott, Bradley McGregor, Aria Olumi, Kimryn Rathmell, Keyan Salari, Vincent Xu

Learning Objectives

Upon completion of this activity, participants will be able to:

• Demonstrate the optimal management of oligometastatic prostate, bladder, and renal cancer
• Explain the role of immunotherapy in the management of bladder, prostate, and renal cancer
• Determine how to incorporate genomic classifiers, multiple parametric MRI, and clinical parameters into selecting optimal patients with prostate cancer for active surveillance or other definitive management approaches
• Apply Level 1 evidence on the use of novel treatment paradigms and updated surveillance options for patients with prostate, renal, bladder, or testicular cancer
• Apply novel minimally invasive treatments for genitourinary malignancies including prostate, bladder, and kidney cancer
• Use multiparametric MRI, fusion biopsy, and novel markers in men at risk for prostate cancer

Speakers

This course features a multidisciplinary faculty of internationally recognized experts in urologic oncology, including leading figures in medical, radiation, and surgical oncology. Keynote speakers include Dr. George Daley, Dean of Harvard Medical School, and Dr. Lindsey Baden, Principal Investigator of the Covid Moderna Trial. The program also incorporates insights from clinicians specializing in prostate, bladder, kidney, and testicular cancers.

Target Audience

• Primary Care Physicians
• Specialty Physicians
• Nurses
• Nurse Practitioners
• Pharmacists
• Physician Assistants
• Psychologists

Why This Topic Matters

The Harvard 21st Biennial Course in Urologic Oncology 2022 provides clinicians and healthcare professionals with in-depth knowledge on the latest diagnostic and therapeutic advances in urologic oncology. This course strengthens clinical expertise in managing prostate, bladder, kidney, and testicular cancers through evidence-based, multidisciplinary approaches.

Presented by a renowned faculty and accessible through MedHub Central, this educational offering supports ongoing professional development in the specialty of urologic oncology. It addresses current challenges and innovations, helping providers improve patient care in this complex field.